SUMMARY Prostacyclin (PGI2) production was diminished when rat aortic rings were incubated with plasma from 5 of 6 patients with the sporadic form of haemolytic uraemic syndrome but was normal in the presence of plasma from 7 patients with the epidemic form of haemolytic uraemic syndrome or from patients with other renal diseases. The reduced PGI2 production was caused by an unstable inhibitor, extractable into polar lipid solvents, in sporadic haemolytic uraemic plasma. These results suggest that there may be at least 2 different pathogenetic mechanisms in epidemic and sporadic haemolytic uraemic syndrome and that the reduced PGI2 production observed in the sporadic type is due to an inhibitor of PGI2 production rather than a deficiency of stimulating factors.
Prostacyclin (PGI2) deficiency has been implicated in the pathogenesis of the haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP),'-4 but there are conflicting views on the pathogenetic mechanisms. Plasma from some patients with HUS shows a reduced capacity to support PGI2 production byendothelial tissue and this has been ascribed to a deficiency of a factor present in normal plasma5 which stimulates PGI production.' This hypothesis is supported by the observation that fresh plasma infusions induce remission in some patients with HUS and TTP.1 6 Other patients, however, have responded instead to plasma exchange,7 suggesting that removal of an inhibitor of PGI2 production may be implicated. More recently excessively rapid degradation of PGI2 in HUS plasma has been observed and has been proposed as a third possible explanation for the PGI2 deficiency. 4 The interpretation of the importance of PGI2 deficiency in HUS is further complicated by the fact that it is not a constant feature of the syndrome and that trials of PGI2 infusions have had only moderate success in reversing the condition. 8 Although the heterogeneity of patients with HUS and TTP has been recognised,9 10 most reports on PGI2 production have failed to distinguish the different subgroups within the HUS spectrum. Epidemiological studies on HUS in children, however, suggest the existence of at least 2 distinct subgroups in the United Kingdom." An epidemic form occurs mainly in summer, in younger children, usually with an explosive onset after diarrhoea, and has a good prognosis. In contrast a sporadic form occurs in older children, with no seasonal variation, developing insidiously without clear prodromal illness or after an upper respiratory infection, and the prognosis for renal function is poor.
In addition to the childhood epidemic and sporadic forms, HUS is seen in association with pregnancy,12 with collagen vascular disease,12 after some infections,12 13 and with drug exposure.12
Clearly, different pathogenetic mechanisms may underlie these different forms of HUS and may account for the disparate results obtained in studies on pathogenesis and in treatment trials in these disorders.
We show that plasma of patients with sporadic HUS (but not epidemic HUS) fails to support PGI2 production by rat aortic rings and that this abnormality is due to the presence of an inhibitory substance. The results of preliminary studies on the nature of the inhibitor are reported.
Patients
HUS was diagnosed in 13 children with microangiopathic haemolytic anaemia, renal faliure, and thrombocytopenia in whom other causes, particularly septicaemia, had been excluded (Table) . Seven younger children aged 11 months to 7 years (cases 1-7) in whom HUS developed acutely after a diarrhoeal prodrome during a summer epidemic were classified as having epidemic HUS. Five older Platelet rich plasma (PRP) for aggregation studies was prepared from normal adults by centrifugation of citrated blood at 300 g for 15 minutes at room temperature. The final platelet count was adjusted to 250-300 x 109/l (250 000-300 000/mm3) by dilution with autologous PPP.
Ability to support PGT2 production. The ability of plasma to support PGI2 production by rat aortic rings was assessed by a modification of the method of Moncada et al.14-PGI2 like activity produced being measured by the inhibitory effect on aggregation of normal human platelets challenged with 2.5 mmol/l adenosine diphosphate (ADP).
Aortic rings (1-2 mm width) were obtained from freshly sacrificed male Wistar rats. After rinsing 3 times in barbitone buffered saline (BBS), pH 7.4, the rings were kept in BBS at 0°C for up to 3 hours until used. In each experiment an aortic ring was incubated at 37°C for 5 minutes with 300 ,±d PPP from either a patient or a control subject, or with 300 ,ul BBS. A 100 ,ul aliquot was then removed and added to 300 V±1 normal PRP. The mixture was stirred for 1 minute in a Payton aggregometer and ADP was then added to a final concentration of 2 5 ,umol/l. In the presence of PPP which had not been incubated with an aortic ring, full aggregation occurred. Inhibition of aggregation was taken to represent the effect of PGI2 like material secreted from the aortic ring into the plasma tested. Each ring that had been incubated with test plasma was then rinsed in BBS for 30 seconds and reincubated in control plasma (and vice versa) for 5 minutes before retesting, so that each ring acted as its own control.
Detection of an inhibitor. To distinguish between inhibition of PGI2 production and lack of PGI2 stimulating factors a second set of cross over experiments were performed in which the production of PGI2 like activity by each aortic ring incubated in test plasma was compared with that produced by the same ring following incubation in BBS. Diminished PGI2 production after incubation of aortic rings in HUS plasma compared with PGI2 production in BBS was taken to indicate the presence of an inhibitor. 
Results
Plasma from 5 of 6 children with sporadic HUS showed decreased ability to support PGI2 production by aortic rings (Fig. 1, Table) . No abnormality of PGI2 production was detected on the incubation of aortic rings with plasma from any of the 7 children with epidemic HUS or of the 9 non HUS patients when compared with the normal adult controls.
Less PGI2 production occurred when aortic rings were incubated in plasma from 3 patients in cases 9 and 11) than when the same ring was incubated in BBS (Fig. 2) . This suggests inhibition of PG!2 production by HUS plasma rather than lack of stimulation. No such inhibitory activity was detected using plasma from the patient in case 13, from any of the epidemic HUS patients, the non HUS patients, or the controls.
The rate at which added PG!2 lost its activity on incubation with plasma from patients in cases 8, 11, and 12, determined by inhibition of platelet aggregation, was no different from that in the presence of normal plasma. This indicates that the effect of these patients' plasma was on the production rather than the degradation of PG!2.
Stability and fractionation studies. Fresh plasma from the patient in case 8 or her plasma stored at -20°for up to 3 months inhibited PG!2 production, but plasma stored at 4°C for 72 hours or dialysed for 72 hours showed neither inhibitory activity nor a failure to stimulate PG!2 production compared with normal plasma. Heating to 56°C for 30 minutes resulted in only a partial loss of the inhibitory activity. No inhibitory activity was detected in the protein fractions, which supported normal PG!2 production, but as these were prepared at 40C or dialysed, inhibitory activity may have been lost. The cyclohexane/ethyl acetate extracted fraction of plasma from patients in cases 8 and 9 inhibited PG!2 production whereas the same fraction of normal plasma had no inhibitory activity (Fig. 3) . No inhibitory activity was detected in the hexane extracted fraction of either HUS or normal plasma.
Discussion
We have shown that plasma from certain patients with childhood HUS fails to support PGI2 production by aortic rings. This parallels previous reports on adult patients with HUS. The abnormality was found only in patients with sporadic HUS, however, and no abnormality of PG!2 production was detected in patients with the commoner epidemic form of HUS or in the other renal diseases studied. Our production occurred on incubation of aortic rings in some samples of HUS plasma than occurred in BBS alone suggests the presence of an inhibitor of PGI2 production in them. Furthermore, prolonged storage or dialysis at 4°C resulted in loss of the inhibitory activity from HUS plasma which then showed normal ability to support PGI2 production. There was no evidence of execssive degradation of added PGI2 in our patients' plasma. Although the cause of the abnormality of PGI2 production in our patients thus differs from that proposed by other workers, it is possible that more than 1 mechanism may induce PGI2 deficiency in different groups of patients.
Our preliminary studies to characterise the inhibitor of PGI2 production indicate that it is a polar lipid, extractable into a mixture of cyclohexane and ethyl acetate. It is of interest that 1 of the earliest known inhibitors of PGI2 synthesis was 15 hydroxyperoxyarachidonic acid'7 and other lipid peroxides are also known to inhibit PGI2 synthesis.'8 Several authors have reported reduced concentrations of antioxidants such as vitamin E,19 superoxide dismutase,20 and transferrin2' in patients with HUS. It is therefore possible that the inhibitor of PGI2 production in the sporadic HUS patients is a lipid peroxide (possibly an arachidonic acid metabolite) produced after an oxidizing insult or resulting from lack of antioxidants in HUS plasma. Further studies are required to define the nature of the inhibitor more precisely and to establish whether its presence is related to the reported defects in antioxidant potential in HUS plasma.
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